arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Zai Lab Ltd

ZLAB
$23.32 ▲ +2.43 (+11.61%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Zai Lab Ltd faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $25.5B
Dividend Yield
Revenue Growth 15.3%
Op. Margin -49.9%
ROIC -31.5%
FCF / Share $-0.15
Trailing P/E
Price / Book 36.1x
FCF Yield
Debt / Equity 0.29
info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$460.16M
↑ +15.3%
Net Income Profit after all expenses
$-175.54M
↑ +31.7%
Operating Margin Operating profit as % of sales
-49.9%
↑ +29.5% 5th
FCF / Share Free cash flow per share
$-0.15
↑ +34.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
26
Financial Health
41
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 31 quarters